Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cingulate Inc. stock logo
CING
Cingulate
$4.04
-2.2%
$4.60
$3.02
$20.83
$21.74M-0.74175,467 shs115,788 shs
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
$0.37
$0.37
$0.22
$3.09
$21.62M1.481.18 million shsN/A
LianBio stock logo
LIAN
LianBio
$0.05
$0.24
$0.27
$4.99
$5.40M0.231.04 million shs44,384 shs
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
$0.54
+15.8%
$0.51
$0.30
$4.28
$22.38M-0.052.21 million shs13.68 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cingulate Inc. stock logo
CING
Cingulate
-2.18%-3.12%-14.41%+5.76%+118.38%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
0.00%0.00%-3.87%+29.20%-50.31%
LianBio stock logo
LIAN
LianBio
0.00%-0.40%+11.11%-86.84%-84.69%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
+15.83%+32.65%+40.70%-34.15%-24.80%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cingulate Inc. stock logo
CING
Cingulate
2.4701 of 5 stars
3.53.00.00.02.30.80.6
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
1.3799 of 5 stars
3.00.00.00.00.61.70.6
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
2.9305 of 5 stars
3.61.00.00.02.93.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cingulate Inc. stock logo
CING
Cingulate
3.00
Buy$26.00543.56% Upside
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
2.00
Hold$2.62616.89% Upside
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
3.25
Buy$8.001,381.48% Upside

Current Analyst Ratings Breakdown

Latest LIAN, ELEV, RVPH, and CING Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/15/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/15/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $2.00
8/8/2025
Cingulate Inc. stock logo
CING
Cingulate
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/27/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
6/10/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform ➝ Market Perform
6/10/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Neutral
6/9/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/9/2025
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/3/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00
5/27/2025
Cingulate Inc. stock logo
CING
Cingulate
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $61.00
5/20/2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $3.00
(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/A$2.32 per shareN/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/A$1.02 per shareN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/A$0.02 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cingulate Inc. stock logo
CING
Cingulate
-$15.55M-$8.48N/AN/AN/AN/A-229.78%-142.28%N/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
-$44.49M-$0.82N/AN/AN/AN/A-74.68%-48.14%11/4/2025 (Estimated)
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$29.92M-$0.79N/AN/AN/AN/AN/A-269.23%N/A

Latest LIAN, ELEV, RVPH, and CING Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
-$0.15-$0.12+$0.03-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cingulate Inc. stock logo
CING
Cingulate
N/AN/AN/AN/AN/A
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cingulate Inc. stock logo
CING
Cingulate
0.16
1.87
1.87
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
0.67
19.40
19.40
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
N/A
0.54
0.54

Institutional Ownership

CompanyInstitutional Ownership
Cingulate Inc. stock logo
CING
Cingulate
41.31%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
83.70%
LianBio stock logo
LIAN
LianBio
74.85%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
63.18%

Insider Ownership

CompanyInsider Ownership
Cingulate Inc. stock logo
CING
Cingulate
5.27%
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
8.10%
LianBio stock logo
LIAN
LianBio
7.59%
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
27.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cingulate Inc. stock logo
CING
Cingulate
205.26 million4.99 millionNot Optionable
Elevation Oncology, Inc. stock logo
ELEV
Elevation Oncology
4059.22 million54.43 millionOptionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
Reviva Pharmaceuticals Holdings, Inc. stock logo
RVPH
Reviva Pharmaceuticals
548.00 million34.96 millionOptionable

Recent News About These Companies

Reviva Narrows Loss 23% in Fiscal Q2
Reviva Dives on Stock Offering
RVPH: M&A Deals Highlight Brilaroxazine Value

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cingulate stock logo

Cingulate NASDAQ:CING

$4.04 -0.09 (-2.18%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$4.06 +0.02 (+0.50%)
As of 08/15/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Elevation Oncology stock logo

Elevation Oncology NASDAQ:ELEV

$0.36 0.00 (0.00%)
As of 07/23/2025

Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.05 0.00 (0.00%)
As of 08/14/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Reviva Pharmaceuticals stock logo

Reviva Pharmaceuticals NASDAQ:RVPH

$0.54 +0.07 (+15.83%)
Closing price 08/15/2025 04:00 PM Eastern
Extended Trading
$0.55 +0.01 (+0.93%)
As of 08/15/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.